Helius Medical Tech Q1 2024 GAAP EPS $(3.08) Misses $(2.70) Estimate, Sales $135.000K Beat $130.500K Estimate

5/13/24 4:19:10 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $HSDT alert in real time by email

Helius Medical Tech (NASDAQ:HSDT) reported quarterly losses of $(3.08) per share which missed the analyst consensus estimate of $(2.70) by 14.07 percent. This is a 30.32 percent increase over losses of $(4.42) per share from the same period last year. The company reported quarterly sales of $135.000 thousand which beat the analyst consensus estimate of $130.500 thousand by 3.45 percent. This is a 21.62 percent increase over sales of $111.000 thousand the same period last year.

Get the next $HSDT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSDT

Date	Price Target	Rating	Analyst
11/15/2021		Outperform → Market Perform	Noble Capital Markets

More analyst ratings

$HSDT
Leadership Updates

Live Leadership Updates

Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors
NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I
9/14/21 7:05:00 AM ET
$HSDT
$LIVN
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Better For You Wellness Appoints Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD to its Board of Directors
Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance
9/2/21 9:29:00 AM ET
$HSDT
$SRNE
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Biotechnology: Commercial Physical & Biological Resarch
Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer
NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Antonella Favit-Van Pelt, M.D., Ph.D. to the position of Chief Medical Officer. "I am very pleased to welcome Dr. Favit-Van Pelt to Helius, who joins our team with a clinical and academic background in Neurology, as well as 20 years of experience advising and leading medical programs for healthcare companies – including both large, globally-diversified corporations and smaller, earlier-stage companies," said Helius CEO, Dane Andreeff. "I look forward to her future cont
7/8/21 7:30:00 AM ET
$TEVA
$JNJ
$BMY
$HSDT
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus

$HSDT
Press Releases

Fastest customizable press release news feed in the world

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET. "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I
11/18/24 8:01:00 AM ET
$HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has initiated a process, in consultation with its financial and legal advisors, to explore a range of strategic alternatives focused on maximizing stockholder value. The deferral of a reimbursement payment determination for the PoNS Controller and inadequate PoNS Mouthpiece pricing issued by CMS in October has limited the Company's ability to advance its operations and impeded its access to traditional financing avenues. Helius
11/18/24 8:00:00 AM ET
$HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. ("Helius" or the "Company") (NASDAQ:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Management will be presenting at 4:30pm ET on October 30th and holding one-on-one investor meetings throughout the day. Interested inv
10/18/24 8:00:00 AM ET
$HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET. "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I
11/18/24 8:01:00 AM ET
$HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus
8/6/24 4:36:06 PM ET
$HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2
5/10/24 9:00:00 AM ET
$HSDT
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Helius Medical Tech Q1 2024 GAAP EPS $(3.08) Misses $(2.70) Estimate, Sales $135.000K Beat $130.500K Estimate

Chat with this insight

Recent Analyst Ratings for $HSDT

$HSDT Market Insights

Live Market Insights

12 Health Care Stocks Moving In Thursday's After-Market Session

Helius Medical Technologies Regains Nasdaq Compliance Following May 9 Financing, Satisfies All Criteria For Continued Listing On Nasdaq Capital Market

Helius Medical Technologies Reports Third-Party Reimbursement For PoNS

$HSDT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)

Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)

Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)

$HSDT SEC Filings

Helius Medical Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Helius Medical Technologies Inc.

SEC Form 10-Q filed by Helius Medical Technologies Inc.

$HSDT Leadership Updates

Live Leadership Updates

Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors

Better For You Wellness Appoints Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD to its Board of Directors

Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer

$HSDT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Helius Medical Tech downgraded by Noble Capital Markets

Noble Capital Markets initiated coverage on Helius Medical with a new price target

LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies

$HSDT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

SEC Form SC 13G filed by Helius Medical Technologies Inc.

SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)

$HSDT Press Releases

Fastest customizable press release news feed in the world

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

$HSDT Financials

Live finance-specific insights

$HSDT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

SEC Form 4 filed by Director Walter Blane

SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S

SEC Form 4 filed by Director Straw Edward M

Recent Analyst Ratings for
$HSDT

$HSDT
Market Insights

$HSDT
Insider Purchases

$HSDT
SEC Filings

$HSDT
Leadership Updates

$HSDT
Analyst Ratings

$HSDT
Large Ownership Changes

$HSDT
Press Releases

$HSDT
Financials

$HSDT
Insider Trading